TIDMPRM

RNS Number : 3096G

Proteome Sciences PLC

29 March 2022

29 March 2022

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Notice of Results

The Directors of Proteome Sciences look forward to updating shareholders on the Company's performance, and on the outlook for 2022, at the time of announcing the 2021 full year results which are scheduled for announcement on Thursday, 31 March 2022.

For further information please contact:

 
 Proteome Sciences plc 
 Dr Mariola Soehngen, Chief Executive       Tel: +44 (0)20 7043 2116 
  Officer 
 Dr Ian Pike Chief Scientific Officer 
 Richard Dennis, Chief Commercial Officer 
 
 Allenby Capital Limited (AIM Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter            Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. ( www.proteomics.com )

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORKVLFLLXLXBBE

(END) Dow Jones Newswires

March 29, 2022 02:01 ET (06:01 GMT)

Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Proteome Sciences Charts.
Proteome Sciences (AQSE:PRM.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Proteome Sciences Charts.